Pharmacokinetic variability 225Ac and 213Bi from vector labeled 225Ac cancer therapy as a function of vector type (antibody vs. small molecule)

Conclusions: This study demonstrated that the use of different targeting vectors for delivery of 225Ac alters the pharmacokinetics and suppliers of unbound 213Bi, to the kidneys. These properties are important for translation to clinical studies as in vivo imaging cannot distinguish between the intact 225Ac-labeled agent and the unbound 213Bi, resulting in an overestimation of the average radiation dose to kidneys and an underestimation of the average radiation dose to the supplying organ (blood and liver, respectively).

Source: Journal of Nuclear Medicine - May 23, 2018 Category: Nuclear Medicine Authors: Josefsson, A., Nedrow, J., Ray, S., Bruchertseifer, F., Morgenstern, A., Pomper, M., Sgouros, G., Hobbs, R. Tags: Clinical Dosimetry Source Type: research